Lawmakers to Trump: Don’t give ‘monopolies’ to companies that develop coronavirus treatments with taxpayer funds
Nearly four dozen lawmakers asked the White House to ensure any treatment that is developed with U.S. taxpayer funds for the fast-moving coronavirus is reasonably priced.
Nearly four dozen lawmakers asked the White House to ensure any treatment for the fast-moving coronavirus that is developed with U.S. taxpayer funds is reasonably priced, an issue that has previously emerged in connection with other nascent medicines due to angst over the cost of prescription drugs.
In a sent Thursday, 46 members of Congress urged the Department of Health and Human Service not to issue an exclusive license to any drug maker that develops a coronavirus treatment over concerns that “providing monopoly rights could result in an expensive medicine that is inaccessible, wasting public resources and putting public health at
